

**South Carolina Department of Health and Human Services (SCDHHS)
Pharmacy and Therapeutics (P&T) Committee
Feb. 4, 2026, Meeting Minutes**

Committee Members Present

Kelly Barth, DO
Divya Ahuja, MD
Jony Bolinger, MD
Patricia Witherspoon, MD
Cheryl Hartvigsen, RPh
Philip Mubarak, MD
Kimberly Rudd, MD
Duncan Norton, MD
Garrett Whittle, PharmD

SCDHHS Team Members Present

Kimberly Bristow, RPh
Brandie Crider, BSBA, CPhT
Sarah Hearn-Bailey, Esq.
Ashley Burton, DNP, FNP-BC
Kevin Wessinger, MD
Tawanna Zeigler, MHSA, CPhT

Prime Therapeutics Staff Present

Lori Ash
Alexis Jones, MHA, MA, CPhT
Blake Cook, RPh
Manisa Bulsara, PharmD

Welcome and Call to Order

Divya Ahuja, MD, called the meeting to order at 4:04 p.m.

Freedom of Information Act/Americans with Disabilities Act Compliance Pledge – This body's official minutes will indicate that this meeting is in compliance with the Freedom of Information Act's mandate that the public be notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

Roll Call

Kimberly Bristow, RPh, welcomed the Pharmacy and Therapeutics (P&T) Committee and encouraged them to attend future meetings in-person. Kimberly Bristow, RPh also asked for attestation forms to be completed and returned.

Approval of Meeting Minutes

The draft minutes from the previous P&T Committee meeting Nov. 5, 2025, were emailed to the members for review prior to the meeting. Garrett Whittle, PharmD, motioned to approve the previous P&T meeting minutes and Duncan Norton, MD, seconded the motion for approval. The minutes were approved unanimously.

State Updates

Kevin Wessinger, MD, notified committee that all providers that order, refer or prescribe services or items for SC Medicaid members must be enrolled in our Medicaid program even if they are not billing Medicaid directly. Providers may enroll through the SCDHHS' website. Providers should select the "Ordering/Referring" provider type when enrolling. Providers who are only enrolled as an Ordering/Referring provider only need to enroll with SCDHHS and not with the state's managed care organizations. Physicians who are already enrolled in Healthy Connections Medicaid are not required to enroll separately as ORP-only providers.

Kimberly Bristow, RPh, notified committee members that beginning Jan. 1, 2026, MCOs were required to reimburse in-state independent pharmacies in parity with FFS methodology for most prescriptions. In-state independent pharmacies are determined by the permit type with SC LLR and enrollment data with SC Medicaid. Several independent pharmacies reached out with reimbursement issues. SC DHHS immediately collaborated with the MCOs and PBMs to resolve these issues. Any claims affected by the coding issues can be reversed and rebilled for FFS reimbursement.

Pharma Updates

Manisa Bulsara, PharmD, informed the committee the state plans to continue utilizing the randomization process for meeting requests in 2026. Those who do not receive a meeting invitation by the end of February 2026 will be randomized for the first set of meetings in 2027. There will be one 40-minute meeting per entity per year. Any questions or concerns can be directed to scpharma@primetherapeutics.com.

New Drugs to Market

Manisa Bulsara, PharmD, announced the newest drugs to the market. They are listed below.

- Modeyso™ (dordaviprone)
- Hernexeos™ (zongertinib)
- Vizz™ (aceclidine ophthalmic solution)
- Javadin® (clonidine oral solution)

- Komzifti™ (ziftomenib)
- Hyrnuo™ (sevabertinib)
- Redemplo™ (plozasiran)
- Lynkuet™ (elinzanetant)
- Itvisma® (onasemnogene abeparvovec-brve)
- Palsonify® (paltusotine)
- Rhapsido™ (remibrutinib)
- Exdensur™ (depemokimab-ulaa)
- Voyxact™ (sibeprenlimab-szsi)
- Aqvesme™ (mitapivat)

Drug Classes for Review

Manisa Bulsara, PharmD, stated there will be a review of several drug classes.

Anti-Infectives: Lincosamides

There was a recommendation to add clindamycin capsules /solution (generic for Cleocin®) as preferred and to add Cleocin® Capsules and Cleocin® Pediatric solution as non-preferred.

Garrett Whittle, PharmD motioned for this to be approved, and Philip Mubarak, MD, seconded the motion. This change was approved unanimously.

Anti-Infectives: Oxazolidinones

The following products were recommended to be added as **preferred**: linezolid suspension/tablet (generic for Zyvox®) as preferred with clinical criteria applied.

The following products were recommended to be added as **non-preferred**: Sivextro® Tablet and Zyvox® Tablet / Suspension.

Patricia Witherspoon, MD motioned for this to be approved pending the review of clinical criteria and Garrett Whittle, PharmD seconded the motion. This change was approved unanimously.

Anti-Infectives: Sulfonamide and Dihydrofolate Reductase Inhibitor, Oral

There was a recommendation to add Sulfamethoxazole-Trimethoprim tablet/suspension (generic for Bactrim®/Bactrim DS®) and Trimethoprim tablet (generic for Primisol®) as preferred, Bactrim® tablet and Bactrim DS® tablet as non-preferred.

Philip Mubarak, MD motioned for this to be approved and Patricia Witherspoon, MD seconded the motion. This change was approved unanimously.

Anti-Infectives: Nitrofurans, Oral

There was a recommendation to add Nitrofurantoin Capsule/Suspension (generic Macrochantin®) and Nitrofurantoin Monohydrate-Macro Capsule (generic Macrobid®) as preferred, with Macrobid® capsule as non-preferred.

Philip Mubarak, MD motioned for this to be approved and Duncan Norton, MD, seconded the motion. This change was approved unanimously.

Drug Classes for Re-Review

Manisa Bulsara, PharmD, leads a review of one drug class.

DPP-4 Inhibitors and Combinations

There was a recommendation to add Janumet® XR Tablet and Onglyza® Tablet to preferred.

Philip Mubarak, MD, motioned to approve. Duncan Norton, MD, seconded the motion. This change was approved unanimously.

Brand to Generic Switch

Manisa Bulsara, PharmD, provided a brand/generic update.

Sacubitril-Valsartan (generic for Entresto®) will be preferred. Brand Entresto® will move to non-preferred. This change will be effective on 4/1/26.

Housekeeping

Manisa Bulsara, PharmD, provided some general updates and reminders.

The pharma email address is scpharma@primetherapeutics.com.

The effective dates for the medications in the classes presented during this meeting are July 1, 2026. The Brand to Generic switch will be effective April 1, 2026.

Manisa Bulsara, PharmD, also provided the committee with Journavx data from Oct. 15, 2025, to January 15, 2026. This was a prior request from the committee. There was a total of 45 patients who received the medication which has decreased since July 1, 2025. Manisa Bulsara, PharmD also noted Journavx® has recently (not even a week ago) received a revision on the current indication. Journavx® was previously approved for moderate to severe acute pain. The revision includes moderate to severe acute pain including post operative pain. Dosing has not changed.

Divya Ahuja, MD, asked for a motion to adjourn. Duncan Norton, MD, motioned. Garrett Whittle, PharmD, seconded the motion.

Closing

The meeting was closed by thanking attendees for their participation and encouraging them to attend the meeting in-person. The next P&T meeting is May 6, 2026, at 4 p.m. The meeting adjourned at 5:04 p.m.